0000000001318807

AUTHOR

Olga Martelli

showing 5 related works from this author

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

2018

Background: The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. Methods: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded Access Program. Objective response rate, progression-free survival and overall survival were evaluated. Patients were monitored for adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events. Results: Among 530 patients evaluated for KRAS mutations, 206 (39%) were positive while 324 (61%) were KRAS wild-type mutations. KRAS status did not influence nivolumab efficacy in terms of …

OncologyAdultMalemedicine.medical_specialtyCancer Researchmedicine.disease_causePredictive markersArticleProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinoma80 and overHumansProgression-free survivalLung cancerNon-Small-Cell LungneoplasmsAgedAged 80 and overbusiness.industryCarcinomaCancerCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseasedigestive system diseasesProgression-Free Survivalrespiratory tract diseasesNivolumabOncologyAdult; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Mutation; Nivolumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); ImmunotherapyOncology; Cancer Research030220 oncology & carcinogenesisExpanded accessMutationFemaleKRASImmunotherapyNivolumabbusinessNon-small-cell lung cancer
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.

2019

Background: In the field of oncological assistance, nowadays we have to deal with a complex scenario where patients got used to obtain a huge amount of information through internet or social media and to apply them in performing their health-related decisions. This landscape requires that clinicians become able to handle therapeutical approaches and adequate skills in communication tools to satisfy the current needs. Our project aimed to build a communication model based on clinical oncologists’ real experiences in order to find a simple way to share with patients all the innovative therapeutical opportunities today available in lung cancer. The final goal is to design a flexible and person…

Communication Internet Lung cancerCancer ResearchKnowledge managementComputer sciencemedia_common.quotation_subjectContext (language use)Quality of life (healthcare)Nuclear Medicine and ImagingRadiology Nuclear Medicine and imagingActive listeningSocial mediaPeer learningmedia_commonTeamworkbusiness.industryCommunicationCommunication; Internet; Lung cancer; Oncology; Radiology Nuclear Medicine and Imaging; Cancer Researchlung cancerCommunication; lung cancer; internetOncologyModels of communicationThe InternetOriginal ArticleinternetbusinessRadiologyTranslational cancer research
researchProduct

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC…

2020

Introduction: Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab. Methods: This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treat…

OncologyMale030213 general clinical medicineLung NeoplasmsNeutrophilsLymphocytenon-small cell lung cancer (NSCLC)DiseaseNSCLCchemistry.chemical_compoundLeukocyte Count0302 clinical medicineAntineoplastic Agents ImmunologicalCarcinoma Non-Small-Cell LungPD-180 and overLeukocytesPharmacology (medical)LymphocytesNon-Small-Cell LungAged 80 and overbiologyGeneral MedicineMiddle AgedPrognosisImmunologicalmedicine.anatomical_structureNivolumab030220 oncology & carcinogenesisLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; Prognosis; Adult; Aged; Aged 80 and over; Antineoplastic Agents Immunological; Biomarkers; Carcinoma Non-Small-Cell Lung; Female; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Retrospective StudiesFemaleNivolumabAdultPD-L1medicine.medical_specialtyLDHAntineoplastic AgentsPLRNONLR03 medical and health sciencesPD-L1Lactate dehydrogenaseInternal medicinemedicineHumansNeutrophil to lymphocyte ratioAgedRetrospective Studiesbusiness.industryCarcinomamedicine.diseaseRheumatologychemistrybiology.proteinLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; PrognosisbusinessBiomarkers
researchProduct

Neutrophil-To-Lymphocyte Ratio (NLR) Platelet-To-Lymphocyte Ratio (PLR), and Outcomes With Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC)…

2020

Provide enhanced digital features for this article This Figshare page contains a Summary Slide. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure informati…

researchProduct